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Abstract 
Background: People with cerebral palsy (CP) may be at increased risk of musculoskeletal 
conditions due to various factors including malnutrition and abnormal levels of skeletal loading. 
This study aimed to compare the incidence of osteoporosis, osteoarthritis and inflammatory 
musculoskeletal diseases between adults with and without CP.    
 
Methods: A population based cohort study was conducted using data from the Clinical Practice 
Research Datalink collected between 1987 and 2015.  Adults with CP were matched to adults 
without CP for age, sex and general practice. Cox models, stratified by matched set and adjusted 
for potential confounders, were fitted to compare the risk of osteoporosis, osteoarthritis and 
inflammatory musculoskeletal diseases.  
 
Results: 1,705 adults with CP were matched to 5,115 adults without CP. Adults with CP had an 
increased risk of osteoporosis in unadjusted (Hazard Ratio (HR) 3.67, 95% Confidence Interval 
(CI) 2.32 to 5.80, p<0.001) and adjusted (HR 6.19, 95% CI 3.37 to 11.39, p<0.001) analyses. No 
evidence of increased risk of inflammatory musculoskeletal diseases was observed in unadjusted 
or adjusted analyses. For osteoarthritis no evidence of increased risk was seen in the unadjusted 
analysis, but evidence of an increased risk was seen when the analysis was adjusted for alcohol 
consumption, smoking status, and mean yearly general practice (GP) visits (HR 1.54, 95% CI  
1.17 to 2.02, p<0.001).  
 
Conclusions After accounting for potential confounding variables, we found that CP is 
associated with increased risk of osteoporosis and osteoarthritis. These findings provide the 
strongest epidemiological evidence to date for increased risk of osteoporosis and osteoarthritis in 
people with CP, and highlight need for clinical awareness of such conditions in this population.  
 
Keywords: cerebral palsy, osteoarthritis, osteoporosis, inflammatory musculoskeletal diseases, 
incidence 
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Introduction 
Cerebral palsy (CP) is considered the most common cause of childhood physical disability with a 
prevalence of approximately 2-3 per 1000 live births.[1] CP is defined by abnormal fine and gross 
motor functioning that results in activity limitations and reduced participation.[1,2] People with 
CP commonly experience musculoskeletal disorders, including spasticity, contractures and bony 
deformities.1 Although CP is considered to be a non-progressive disorder, people with CP often 
report that musculoskeletal disorders and function worsen with age.[3] Notably, nearly one-third 
of adults with CP report experiencing musculoskeletal pain that is associated with deteriorating 
physical function.[4,5] 
 
Longstanding abnormalities in the amount and pattern of loading of musculoskeletal tissues are 
potential risk factors for various musculoskeletal conditions. It is widely considered that people 
with CP are at increased risk of osteoporosis (OP) due in part to the impact of decreased weight 
bearing on bone mineral density throughout childhood. Peak bone mass is established through 
childhood to early adulthood [6] and clinically significant osteopenia appears to be common in 
children and adolescents with CP.[7] A number of small studies have indicated abnormal bone 
microarchitecture in adults with cerebral palsy [8-10] and a recent systematic review found 
evidence to suggest this is also present in ambulatory people with CP.[11] Moreover, there is 
recent cross-sectional evidence that adults with CP have higher prevalence of fractures as 
compared to adults without CP, even after adjusting for osteoporosis.[12] There is a dearth of high 
quality evidence however relating to the prevalence of OP in the adult CP population.  Abnormal 
loading and movement throughout childhood development can also impact the morphology and 
health of joints,[13] raising the risk of developing arthropathies such as osteoarthritis (OA).  
 
A cross-sectional study of multimorbidity in a sample of middle aged adults with CP found a 
40% prevalence of osteopenia/OP and a 27% prevalence of OA. [14] The co-existence of 
osteoarthritis and osteopenia/ OP was present in 17% of participants. However the absence of a 
comparable control group without CP in this study precluded estimation of the increased risk of 
these conditions in adults with CP. A further cross-sectional study from a single clinical centre 
[15] in the US found an increased prevalence of osteopenia, osteoporosis and musculoskeletal 
morbidity in adults with CP compared to adults without CP. 
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In a study of national survey data in the USA, Peterson et al.[16]  found a 15.3% increase in the 
prevalence of joint pain and a 14% increase in the prevalence of arthritis in people with CP 
compared to people without CP, though the study did not differentiate the type of arthritis 
studied or the cause of joint pain. In a cross-sectional study of adults with CP from a single 
clinical centre in the USA, Whitney et al.[17] reported a higher prevalence of OP, OA and 
rheumatoid arthritis (RA) than those reported from population based estimates. They also 
reported a greater odds of these conditions with increased age. While there is no clear 
mechanism by which CP might increase the risk of rheumatoid arthritis, or other systemic 
inflammatory musculoskeletal conditions those authors suggested putative mechanisms including 
an “accelerated ageing” clinical phenotype leading to immunosenescence as well as 
immunosuppression related to CP. Any such mechanism is currently speculative. However, this 
study also lacked any direct comparison with a sample without CP, was cross-sectional, took its 
sample from a single clinical centre and did not include a broader spectrum of inflammatory 
musculoskeletal diseases. 
 
Our aim was to assess if the risk of OA, OP and inflammatory musculoskeletal diseases among 
adults with CP differs from people without CP by comparing the incidence of these conditions in 
a population-based sample using longitudinal data from routinely collected UK primary care 
records. These conditions were the chosen focus of the study as it is widely considered that at 
increased risk of OP and OA exists, but there is a paucity of high quality evidence to estimate the 
size of that risk, and because a prior cross-sectional study suggested an increased risk of RA in 
this group. 
      
Patients and Methods 
Study design and data source 
A matched cohort study was conducted using data from the UK Clinical Practice Research 
Datalink (CPRD). The CPRD contains primary care data routinely collected via electronic health 
records from general practices in the UK. Data collection began in 1987 and we used data 
obtained during the period 1 January 1987 to 30 November 2015. The CPRD includes data on 
clinical events, prescriptions, preventative care, referrals and hospital admissions and data are 
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largely representative of the UK population.[18] Data from the CPRD have been used to conduct 
approximately 1,000 published studies including studies examining the incidence of OA, OP and 
inflammatory arthritis.[19-21]   
 
Participants  
Read codes are used to record clinical diagnoses in primary care in the UK. All patients, aged 18 
years and older, with at least one record of CP (as identified by Read codes in Supplementary 
material S1) occurring during the study period with data that met the definition for research-
standard follow-up were included in the study. The CPRD performs quality checks to determine 
if data are acceptable for use in research. Firstly, an “up to standard date” is identified for each 
practice, which indicates the date at which the practice is considered to have continuous high 
quality data fit for use in research. Secondly, patient data is checked for a number of issues and 
excluded if they have non-continuous follow-up or poor data recording. The start of follow-up 
(hereafter the “index date”) for patients with CP was the latest of: the date the patient registered 
with the general practice, the date the data were considered research-standard, or the 1st January 
of the year in which the patient turned 18 years of age. Patients with a record of CP were 
matched to three control patients without CP on age (within 3 years in either direction), sex and 
general practice (GP). The index date for control patients was set to be the same as that of their 
matched case. Controls had a complete history for the duration of their case’s follow-up. Patients 
were followed to the earliest of: (1) transfer out of CPRD; (2) end of the study period; (3) 
practice last collection date; (4) death; or (5) first event of the outcome.  
 
Outcomes 
A first event of OA, OP, and inflammatory musculoskeletal diseases was identified using Read 
code lists for OA, “rheumatoid arthritis, other inflammatory polyarthropathies and systemic 
connective tissue disorders” and OP (code lists available in supplementary information S2-4).  
 
Other characteristics 
Smoking status (current smoker, ex-smoker, non-smoker) and alcohol consumption (current 
drinker, ex-drinker, or non-drinker) were identified. Where multiple records of smoking status 
and alcohol consumption were available the earliest record after the patient turned 18 years of 
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age was used for the analyses. We also identified mean yearly GP visits, calculated as total 
number of face-to-face or telephone consultations from start of follow-up to censoring, or first 
event of OA, OP, and inflammatory musculoskeletal diseases, respectively, divided by total 
years of follow-up. Finally, we identified people who had experienced a wrist fracture during the 
follow-up period, prior to the first event of OP if applicable.   
 
Statistical analysis 
Descriptive statistics were used to report patient characteristics at start of follow-up. 
For each outcome, a separate Cox model with an underlying age timescale, stratified by matched 
set, was fitted to examine the association between CP and incidence of each MSK condition.[22] 
Initially, unadjusted hazard ratios were calculated. All Cox models were then adjusted for 
smoking status, alcohol consumption, and mean yearly GP visits. We adjusted for mean yearly 
GP visits, as patients with CP may have more GP visits, and patients who consulted their GP 
more frequently may be more likely to receive a diagnosis of the respective conditions. As the 
mechanism underlying missing records for smoking status and alcohol consumption in primary 
care data is likely to be missing not at random, as opposed to missing at random,[23,24] multiple 
imputation is not appropriate for these data. Smoking status and alcohol consumption were 
dichotomised as current smokers and non-current smokers, and current drinkers and non-current 
drinkers, respectively. As Marsden[23,24]  identified that missing data for smoking status most 
likely pertain to ex-smokers and non-smokers, and missing data for alcohol consumption most 
likely pertain to current drinkers,[23,24] missing data were assumed to relate to non-current 
smokers and current drinkers, respectively.   
 
Model checking and sensitivity analyses 
For the analysis relating to OP, we conducted a sensitivity analysis by further adjusting the 
model for wrist fracture. Wrist fracture is a potential confounding factor for the association 
between CP and OP as people who experience a wrist fracture may be more likely to receive a 
diagnosis of OP, and people with CP may be more likely to experience a fracture due to an 
increased risk of falls. Further, sensitivity analyses were conducted to examine the impact of 
assumptions regarding the mechanisms of missing data on conclusions by: (1) excluding missing 
data for smoking status and alcohol consumption (i.e. performing complete case analysis); and 
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(2) recategorising smoking status as current smokers and non-current smokers, with missing data 
assumed to relate to current smokers, and recategorising alcohol consumption as current drinkers 
and non-current drinkers with missing records assumed to pertain to non-current drinkers. As 
each patient with CP may not be matched for age, sex and general practice to three patients 
without CP in complete case analysis, for this analysis we used Cox models with an underlying 
age timescale adjusted for age, sex, region, smoking status, alcohol consumption and GP visits. 
The validity of the assumption of proportional hazards was assessed by plotting scaled 
Schoenfeld residuals against time and including interaction terms between time and each 
predictor variable, respectively, for all models. Martingale residuals were plotted against mean 
yearly GP visits and age, where applicable, to examine if there was a linear association between 
each variable and the outcome. 
 
The CPRD has obtained research ethics approval from a National Research Ethics Service 
Committee for purely observational research using anonymised CPRD data. The protocol was 
approved by the Independent Scientific Advisory Committee for MHRA Database Research 
(protocol no. 16_077R2A). 
 
Results 
 1,705 patients with CP who met the inclusion criteria were identified and matched to 5,115 patients 
without CPfor age, sex and practice. The characteristics of patients with and without CP at start of follow-
up are reported in Table 1. The distribution of exposures, outcomes and potential confounders across 
patients with complete and incomplete data is presented in Supplementary material S5. The distribution of 
data relating to smoking status and alcohol status, before and after imputation, is reported in 
Supplementary material S6. For patients with CP, median follow-up time was 6.72 yr (range 0.003 yr to 
27.94 yr) for osteoarthritis, 7.11 yr (range 0.04 yr to 27.94 yr) for inflammatory musculoskeletal diseases, 
and 7.08 yr (range 0.003 yr to 27.94 yr) for osteoporosis. For patients without CP, median follow-up time 
was 10.23 yr (range 0.01 yr to 28.01 yr) for OA, 10.91 yr (range 0.10 yr to 28.01 yr) for people without 
CP for inflammatory musculoskeletal diseases, and 10.92 yr (range 0.14 yr to 28.01 yr) for OP. The 
median (IQR) age of first diagnosis of osteoporosis was 55.1 years (47.9 years to 63.8 years) in 
people with CP, and 68.6 years (55.9 years to 77.8 years) in people without CP. For OA the 
median (IQR) age of first diagnosis was 53.0 years (46.2 years to 66.2 years) in people with CP 
and 59.1 years (49.5 years to 70.0 years) in people without CP. The median (IQR) age of first 
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diagnosis of inflammatory musculoskeletal diseases was 38.9 years (36.1 years to 51.0 years) in 
people with CP and age was 52.7 years (40.1 years to 63.8 years) in people without CP. 
  
 
Unadjusted hazard ratios (HR) (Table 2) showed no evidence that patients with CP had a higher 
risk of OA (HR: 1·07, 95% CI 0.85 to 1.35, p=0.552) or inflammatory musculoskeletal diseases 
(HR: 0.76, 95% CI 0.41 to 1·40, p=0·376). There was evidence from the unadjusted analysis that 
patients with CP had increased risk of OP (HR: 3.67, 95% CI 2.32 to 5.80, p<0.001) compared to 
patients without CP. After adjusting for smoking, alcohol consumption, and mean yearly GP 
visits (Table 2), there was evidence that people with CP had increased risk of OA (HR:  1.54, 
95% CI 1.17 to  2.02, p=0.002) and OP (HR: 6.19, 95% CI  3.37 to 11.39 , p<0.001) compared to 
patients without CP, but no evidence of increased risk of inflammatory musculoskeletal diseases 
among patients with CP (HR: 0.89 , 95% CI 0.45 to 1.75, p=0.731).  
 
Plots of Martingale residuals suggested that a linear association existed between each outcome 
and GP visitsfor all models. There was no evidence that the proportional hazards assumption was 
violated for any model. Sensitivity analyses did not change the conclusions of the study. 
Adjusting the final model for wrist fracture resulted in an increase in the HR for OP (HR:  7.24, 
95% CI 3.79 to 13.82, p<0.001; Table 3). However, the confidence interval included the estimate 
obtained from the primary analysis. Complete case analysis resulted in similar effect estimates 
and identical conclusions to the primary analysis for OP and inflammatory musculoskeletal 
diseases. For osteoarthritis, complete case analysis resulted in a larger hazard ratio for CP 
compared to the primary analysis (HR:  2.05, 95% CI 1.60 to 2.62; Table 3). Conducting the 
analysis with missing data on smoking status recategorised as current smokers, and missing data 
on alcohol consumption recategorised as non-current drinkers resulted in effect estimates and 
95% CI that were very similar to those obtained from the primary analysis (Table 3).  
 
Discussion 
The principal finding of this population-based cohort study was that adults with CP had a higher 
incidence of OP and OA as compared to adults without CP, after accounting for age, sex, general 
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practice, alcohol consumption, smoking status, and GP visits; however; no differences were 
observed in the incidence of inflammatory musculoskeletal diseases.  
 
This is the largest study to date to investigate the incidence of MSK conditions in adults with CP. 
There is a dearth of epidemiological evidence in relation to this topic, though reduced bone mass 
has been observed in children with spastic quadriplegia,[25] and there is some evidence of raised 
fracture rates in children and adults with CP.[12,26] These findings have implications for the 
clinical management of people with CP. Osteoporosis and its sequelae might be prevented or 
mitigated using  various approaches including dietetic intervention, weight-bearing physical 
activities, clinical screening, or pharmacological interventions. In the UK the National Institute 
of Health and Care Excellence (NICE) guideline on CP in children and young people [27] 
recommend awareness of the risk of low bone mineral density and low -impact fractures, 
assessment of dietary calcium/vitamin D intake in those with risk factors, and the creation of 
individualized treatment plans to reduce the risk. The 2019 NICE guideline on CP in adults [28] 
recognizes the potential increased risk of osteoporosis and arthritis, and recommends monitoring 
adults with CP for these conditions, despite identifying minimal and very low quality evidence 
relating to the incidence of OP and no evidence relating to the incidence of OA. Our findings 
provide more robust evidence to support these recommendations. 
 
It is a commonly held view that chronic abnormal joint loading in people with CP increases the 
risk of OA via impact on joint development and accelerated wear and tear. [13,29] Previous studies 
have suggested a rise in the prevalence of joint pain and arthritis in people with CP.[16,17] It is 
likely that OA may be influenced by factors such as mobility status and, potentially, obesity. In 
terms of mobility status, it is likely that its relationship with OA risk might not be linear. There is 
some exploratory evidence for higher prevalence of OA in non-ambulatory versus ambulatory 
people with CP [15] but it is also plausible that risk of OA might be raised in ambulatory people 
with high BMI. In our study, the low proportion of patients with CP with overweight or obesity, 
compared to patients without CP, and our inability to adjust for ambulatory status might have 
contributed to the rather marginal results seen for OA. Although there is substantial variation in 
the prevalence of obesity among adults with CP across studies (7.3% to 41.4%),[30] the 
prevalence of 9.6% reported herein is not unusually low nor dissimilar to that found in a small 
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cross-sectional study of adults with CP in Ireland.[31] It is also possible that people with CP may 
be less likely to be attributed a diagnosis of OA from their clinician despite reporting symptoms 
consistent with the diagnosis. Clinicians may be less inclined to specifically identify symptoms 
as an issue that they presume to be the inevitable sequelae of living with CP or may not prioritise 
joint pain over other problems that the patient is reporting. It is also possible that clinicians may 
classify joint pains using other descriptors. As such our results might underestimate the incidence 
of OA in this group. 
 
That we observed no increase in the incidence of inflammatory musculoskeletal diseases is at 
odds with the findings of Whitney et al,[17] who showed an increased prevalence of RA in a clinic 
based sample people with CP compared to general population estimates. That study [17] was not 
population-based, did not make a direct comparison with an equivalent sample of people without 
CP and looked specifically at rheumatoid arthritis rather than the broader scope of systematic 
inflammatory MSK conditions. As we included rheumatoid arthritis within a broader category of 
inflammatory musculoskeletal diseases, it is possible that an effect may have been missed.  
 
This is the first study to compare the incidence of OA, OP and inflammatory musculoskeletal 
diseases between adults with and without CP using a relatively large cohort of adults with CP. 
We were able to adjust for several potential confounding factors, and our findings were robust to 
sensitivity analyses. It should be acknowledged that residual confounding may still be present as 
we were unable to adjust for mobility status or physical activity. However, caution should be 
taken when adjusting for these factors as they are likely to be mediators of the association 
between CP and both OA and OP, and conditioning on them may itself induce bias.[31] 
Exploration of mobility status as an effect modifier is warranted in future studies to improve our 
understanding of the impact of severity of disability on risk for these conditions. In our analyses, 
we did not adjust for BMI. It has been shown that BMI is an imperfect estimation of body 
composition in people with CP,[32] as it overestimates fat free mass and underestimates fat mass. 
This inaccuracy is increased in people with more severe CP, due to diminished lean mass. As we 
did not have measure of the severity of CP, we were unable to account for this in our analyses 
which may have led to error. In addition, there was a large amount of missing data for BMI and 
imputation of missing values may have compounded this inaccuracy. In the analysis relating to 
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osteoporosis we conducted a sensitivity analysis by adjusting for wrist fracture as a potential 
confounding factor, as people who experience a wrist fracture may be more likely to receive a 
diagnosis of OP, and people with CP may be more likely to experience a fracture due to an 
increased risk of falls. However, we did not adjust for other specific fragility fractures or fragility 
fractures in general due to concerns surrounding the consistent use of read codes for these events. 
As a result of matching patients on practice, practice-level rather than patient-level 
socioeconomic status was adjusted for in the analysis. Although the Index of Multiple 
Deprivation scores may be used to categorise patients in CPRD according to patient- and 
practice-level socioeconomic status, it is only available for approximately half of patients in 
CPRD and these data were not obtained.  
 
 Further limitations include the possibility that the diagnostic code lists were incomplete, 
identification of cases is dependent on the quality of original recording in the database, and a 
substantial proportion of data were missing for smoking status, alcohol consumption. To assess 
the impact of the potentially strong assumptions that we made when imputing missing data, we 
conducted two sensitivity analyses; a complete case analysis and analysis recategorising missing 
data relating to smoking status and alcohol consumption as smokers and non-drinkers, 
respectively. These sensitivity analyses did not change the conclusions of the study and support 
the robustness of these findings to different underlying mechanisms of missing data.   
 
This is the first population-based cohort study examining the incidence of OA, inflammatory 
musculoskeletal diseases and OP in adults with CP. Our study demonstrated that adults with CP 
have a higher incidence of OP and OA compared to adults without CP after accounting for 
potential confounding variables. Despite previous studies identifying a high prevalence of joint 
pain and functional deterioration among people with CP, there is a dearth of literature on the 
burden of musculoskeletal disorders in this population. These findings support the need for 
clinical awareness of OA and OP as potential comorbidities in adults with CP. Further research is 
required into effective management of these conditions in adults with CP.     
 
Contributors: All authors were involved in study design and approved the final manuscript. JR 
conducted the statistical analysis. NOC wrote the first draft of the manuscript. 
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Table 1. Patient characteristics at start of follow-up 
Variable Patients with 
CP 
(n=1,705) 
Patients without 
CP 
(n=5,115) 
Total 
(n=6,820) 
Sex    
   Males 907 (53.2) 2,721 (53.2) 3,628 (53.2) 
Age, yr    
   Median (IQR) 29 (20 to 42) 29 (20 to 42) 29 (20 to 42) 
   <30 877 (51.4) 2,631 (51.4) 3,508 (51.4) 
   30-39 336 (19.7) 1,008 (19.7) 1,344 (19.7) 
   40-49 223 (13.1) 669 (13.1) 892 (13.1) 
   50-59 135 (7.9) 405 (7.9) 540 (7.9) 
   ≥60 134 (7.9) 402 (7.9) 536 (7.9) 
    
    
    
    
    
    
    
    
Smoking status    
   Current smoker 213 (12.5) 1,511 (29.5) 1,724 (25.3) 
   Ex-smoker 65 (3.8) 424 (8.3) 489 (7.2) 
   Non-smoker 1,261 (74.0) 2,740 (53.6) 4,001 (58.7) 
   Missing 166 (9.7) 440 (8.6) 606 (8.9) 
Alcohol consumption    
   Current drinker 724 (42.5) 3,142 (61.4) 3,866 (56.7) 
   Ex-drinker 15 (0.9) 40 (0.8) 55 (0.8) 
   Non-drinker 527 (30.9) 640 (12.5) 1,167 (17.1) 
   Missing 439 (25.8) 1,293 (25.3) 1,732 (25.4) 
Practice regiona    
   North England and 
Scotland 
473 (27.7) 1,419 (27.7) 1,892 (27.7) 
   Midlands and Wales 603 (35.4) 1,809 (35.4) 2,412 (35.4) 
   South England 587 (34.4) 1,761 (34.4) 2,348 (34.4) 
   Northern Ireland 42 (2.5) 126 (2.5) 168 (2.5) 
Wrist fracture    
  Presence of 17 (1.0) 69 (1.4) 86 (1.3) 
Average yearly GP visits 
(OA) 
   
Median (IQR) 7.97 (4.04 to 
14.45) 
3.48 (1.39 to 
6.99) 
4.28 (1.73 to 
8.74) 
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Data reported as no. (%) unless stated otherwise 
CP: cerebral palsy; IQR: interquartile range; BMI: ; SD: standard deviation 
aNorth England and Scotland: North East England, North West England, Yorkshire, Scotland; 
Midlands and Wales: East Midlands, West Midlands, East of England, Wales; South England: 
South West England, South Central England, London, South East England 
range 0 to 154.70  0 to 97.40 0 to 154.70 
   0 - 1.9 visits 199 (11.7) 1704 (33.3) 1903 (27.9) 
   2 - 11.9 visits 942 (55.3) 2916 (57.0) 3858 (56.6) 
   ≥ 12 visits 564 (33.1) 495 (9.7) 1059 (15.5) 
Average yearly GP visits 
(RA) 
   
Median (IQR) 8.48 (4.47 to 
14.82) 
3.77 (1.55 to 
7.52) 
4.71 (1.94 to 
9.35) 
Range 0 to 154.70 0 to 97.40 0 to 154.70 
   0 - 1.9 visits 164 (9.6) 1573 (30.8) 1737 (25.5) 
   2 - 11.9 visits 952 (55.8) 2964 (58.0) 3916 (57.4) 
   ≥ 12 visits 589 (34.6) 578 (11.3) 1167 (17.1) 
Average yearly GP visits 
(OP) 
   
Median (IQR) 8.37 (4.38 to 
14.74) 
3.79 (1.56 to 
7.52) 
4.70 (1.95 to 
9.34) 
Range 0 to 154.70 0 to 97.4 0 to 154.70 
   0 - 1.9 visits 167 (9.8) 1565 (30.6) 1732 (25.4) 
   2 - 11.9 visits 955 (56.0) 2969 (58.0) 3924 (57.5) 
   ≥ 12 visits 583 (34.2) 581 (11.4) 1164 (17.1) 
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Table 2. Incidence rate of eachcondition , unadjusted and adjusted hazard ratios for each 
condition comparing patients with cerebral palsy to patients without cerebral palsy 
(n=6,820) 
 
 
 
Events,  
No. (%) 
Total 
person-
years 
(1,000s) 
Incidence,  
per 1,000 
person-
years 
Unadjuste
d hazard 
ratio 
(95% CI) 
p 
value 
Adjusted 
hazard ratioa 
(95% CI) 
p 
value 
Osteoarthritis 
CP 104 
(6.1) 
13.9 7.46 1.07 (0.85 
to 1.35) 
0.552 1.54 (1.17 to  
2.02) 
0.002 
non-
CP 
370 
(7.2) 
53.8 6.88 
Inflammatory musculoskeletal diseases 
CP 13 (0.8) 14.5 0.89 0.76 (0.41 
to 1.40) 
0.376 0.89 (0.45 to 
1.75) 
0.731 
non-
CP 
62 (1.2) 56.4 1.10 
Osteoporosis 
CP 41 (2.4) 14.4 2.85 3.67 (2.32 
to 5.80) 
<0.001 6.19 (3.37 to 
11.39) 
<0.001 
non-
CP 
53 (1.0) 56.5 0.94 
CP: cerebral palsy; CI: confidence interval  
aadjusted for alcohol, smoking, GP visits 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Adjusted hazard ratios from sensitivity analyses, for each condition comparing 
patients with cerebral palsy to patients without cerebral palsy  
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Osteoporosis model 
adjusted for wrist 
fracture (n=6,820) 
Complete case analysis 
(n=5,075) 
Reclassified smoking 
status and alcohol 
consumptiona (n=6,820) 
 Adjusted HRb 
(95% CI) 
p value Adjusted HRc 
(95% CI) 
p value Adjusted HRd (95% 
CI) 
p value 
OA - -  2.05 (1.60 to 2.62) <0.001 1.65 (1.25 to 2.19) <0.001 
IMD 
 
- -  0.76 (0.38 to 1.51)  0.434 0.96 (0.48 to 1.91) 0.904 
OP 7.24 (3.79 to 
13.82) 
<0.001 3.03 (1.89 to 4.87) <0.001 5.85 (3.19 to 10.72) <0.001 
CI: confidence interval 
amissing data for smoking status and alcohol consumption classified as current smokers and 
non-current drinkers, respectively  
badjusted for alcohol, smoking, GP visits, and wrist fracture  
cadjusted for  age, sex, region, alcohol, smoking and GP visits 
dadjusted for alcohol, smoking and GP visits 
OA osteoarthritis, OP osteoporosis, IMD inflammatory musculoskeletal diseases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary information 
 
S1 Text. Read codes indicating cerebral palsy 
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Read code Read term 
F23y400  Ataxic diplegic cerebral palsy  
F23y000  Ataxic diplegic cerebral palsy  
F137.11  Athetoid cerebral palsy  
F137000  Athetoid cerebral palsy  
F2B..00  Cerebral palsy  
F2Bz.00  Cerebral palsy NOS  
F230100  Cerebral palsy with spastic diplegia  
F23..00  Congenital cerebral palsy  
F23y300  Dyskinetic cerebral palsy  
F23..12  Infantile cerebral palsy  
F23y200  Spastic cerebral palsy  
F230111  Spastic diplegic cerebral palsy  
F2B1.00  Spastic hemiplegic cerebral palsy  
F2B0.00  Spastic quadriplegic cerebral palsy  
F23yz00  Other infantile cerebral palsy NOS  
Fyu9000  [X]Other infantile cerebral palsy  
F23y.00  Other congenital cerebral palsy  
F23y100  Flaccid infantile cerebral palsy  
F2By.00  Other cerebral palsy  
Fyu9.00  X]Cerebral palsy and other paralytic syndromes 
F23z.00  Congenital cerebral palsy NOS  
F23..11  Congenital spastic cerebral palsy  
F23y600  Choreoathetoid cerebral palsy  
 
 
 
S2 Read Codes for Osteoporosis (adapted from 
https://clinicalcodes.rss.mhs.man.ac.uk/medcodes/article/1/codelist/osteoporosis/ ) 
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Read 
code 
Read term 
585O.00 Quantitative ultrasound scan of heel - result osteoporotic 
58E4.00 Forearm DXA scan result osteoporotic 
58EA.00 Heel DXA scan result osteoporotic 
58EG.00 Hip DXA scan result osteoporotic 
58EM.00 Lumbar DXA scan result osteoporotic 
58EV.00 Femoral neck DEXA scan result osteoporotic 
N330.00 Osteoporosis 
N330000 Osteoporosis, unspecified 
N330100 Senile osteoporosis 
N330200 Postmenopausal osteoporosis 
N330300 Idiopathic osteoporosis 
N330400 Dissuse osteoporosis 
N330500 Drug-induced osteoporosis 
N330600 Postoophorectomy osteoporosis 
N330700 Postsurgical malabsorption osteoporosis 
N330800 Localized osteoporosis - Lequesne 
N330900 Osteoporosis in multiple myelomatosis 
N330A00 Osteoporosis in endocrine disorders 
N330B00 Vertebral osteoporosis 
N330C00 Osteoporosis localized to spine 
N330D00 Osteoporosis due to corticosteroids 
N330z00 Osteoporosis NOS 
N331200 Postoophorectomy osteoporosis with pathological fracture 
N331300 Osteoporosis of disuse with pathological fracture 
N331400 Postsurgical malabsorption osteoporosis with path fracture 
N331500 Drug-induced osteoporosis with pathological fracture 
N331600 Idiopathic osteoporosis with pathological fracture 
N331800 Osteoporosis + pathological fracture lumbar vertebrae 
N331900 Osteoporosis + pathological fracture thoracic vertebrae 
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N331A00 Osteoporosis + pathological fracture cervical vertebrae 
N331B00 Postmenopausal osteoporosis with pathological fracture 
N331M00 Fragility fracture due to unspecified osteoporosis 
N331N00 Fragility fracture 
NyuB000 [X]Other osteoporosis with pathological fracture 
NyuB100 [X]Other osteoporosis 
NyuB200 [X]Osteoporosis in other disorders classified elsewhere 
NyuB800 [X]Unspecified osteoporosis with pathological fracture 
N330z00 Osteoporosis NOS 
66a5.00 Osteoporosis - no treatment 
 
 
S3 Read Codes for inflammatory Arthoparthies (adapted from 
http://www.phpc.cam.ac.uk/pcu/cprd_cam/codelists/ )   
 
 
Read 
code 
Read term 
N04z.00 inflammatory polyarthropathy nos 
M154100 discoid lupus erythematosus 
N241z00 myalgia or myositis nos 
N040E00 rheumatoid arthritis of tibio-fibular joint 
N044.00 chronic post-rheumatic arthropathy 
N043.00 juvenile rheumatoid arthritis - still's disease 
N040M00 rheumatoid arthritis of ip joint of toe 
N04X.00 seropositive rheumatoid arthritis, unspecified 
M154700 subacute cutaneous lupus erythematosus 
N042200 rheumatoid nodule 
N04y000 rheumatoid lung 
N040700 rheumatoid arthritis of wrist 
N040P00 seronegative rheumatoid arthritis 
N043200 pauciarticular juvenile rheumatoid arthritis 
N042000 rheumatic carditis 
N001100 crest syndrome 
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N040L00 rheumatoid arthritis of lesser mtp joint 
M160.00 psoriatic arthropathy 
N10..00 inflammatory spondylopathies 
N004.00 polymyositis 
M160z00 psoriatic arthropathy nos 
N040300 rheumatoid arthritis of sternoclavicular joint 
N043300 monarticular juvenile rheumatoid arthritis 
Nyu1500 [x]other juvenile arthritis 
N045300 juvenile arthritis in crohn's disease 
N040N00 rheumatoid vasculitis 
N003X00 dermatopolymyositis, unspecified 
N045500 juvenile rheumatoid arthritis 
N001000 progressive systemic sclerosis 
M160.11 psoriatic arthritis 
N000.00 systemic lupus erythematosus 
N042.00 other rheumatoid arthropathy + visceral/systemic involvement 
N040200 rheumatoid arthritis of shoulder 
N040G00 rheumatoid arthritis of subtalar joint 
N241200 fibromyositis nos 
N04..11 inflammatory polyarthropathy 
N043000 juvenile rheumatoid arthropathy unspecified 
N040400 rheumatoid arthritis of acromioclavicular joint 
M160000 psoriasis spondylitica 
M154.00 lupus erythematosus 
N041.00 felty's syndrome 
N045200 juvenile arthritis in psoriasis 
N065.00 unspecified polyarthropathy or polyarthritis 
N241100 myositis unspecified 
N241.00 myalgia and myositis unspecified 
N040900 rheumatoid arthritis of pip joint of finger 
N040S00 rheumatoid arthritis - multiple joint 
N040C00 rheumatoid arthritis of sacro-iliac joint 
N040J00 rheumatoid arthritis of other tarsal joint 
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N001.12 systemic sclerosis 
N040.00 rheumatoid arthritis 
N040600 rheumatoid arthritis of distal radio-ulnar joint 
N003000 juvenile dermatomyositis 
N003.00 dermatomyositis 
N04y200 adult-onset still's disease 
N042100 rheumatoid lung disease 
N04y.00 other specified inflammatory polyarthropathy 
N043100 acute polyarticular juvenile rheumatoid arthritis 
N045400 juvenile arthritis in ulcerative colitis 
M154z00 lupus erythematosus nos 
N042z00 rheumatoid arthropathy + visceral/systemic involvement nos 
N040800 rheumatoid arthritis of mcp joint 
N045100 juvenile seronegative polyarthritis 
N040H00 rheumatoid arthritis of talonavicular joint 
N040A00 rheumatoid arthritis of dip joint of finger 
N040D00 rheumatoid arthritis of knee 
N040Q00 rheumatoid bursitis 
N040500 rheumatoid arthritis of elbow 
N045600 pauciarticular onset juvenile chronic arthritis 
N045.00 other juvenile arthritis 
N040B00 rheumatoid arthritis of hip 
N04yz00 other specified inflammatory polyarthropathy nos 
N043z00 juvenile rheumatoid arthritis nos 
N04y100 sero negative arthritis 
N20..00 polymyalgia rheumatica 
N040K00 rheumatoid arthritis of 1st mtp joint 
N040F00 rheumatoid arthritis of ankle 
N04..00 rheumatoid arthritis and other inflammatory polyarthropathy 
N045000 juvenile ankylosing spondylitis 
N047.00 seropositive errosive rheumatoid arthritis 
N040T00 flare of rheumatoid arthritis 
 
25 
 
 
 
S4. Read codes for osteoarthritis (adapted from 
http://www.phpc.cam.ac.uk/pcu/cprd_cam/codelists/ )    
 
Read code Read term 
N05zS00 osteoarthritis nos, of 1st mtp joint 
N11z.11 osteoarthritis spine 
N11D300 osteoarthritis of spine nos 
N05z713 toe osteoarthritis nos 
N05zF00 osteoarthritis nos, of mcp joint 
N03xF00 arthritis associated with other disease, talonavicular joint 
N05..00 osteoarthritis and allied disorders 
N03x600 arthritis associated with other disease, mcp joint 
N051.00 localised, primary osteoarthritis 
N053400 localised osteoarthritis, unspecified, of the hand 
N05zz00 osteoarthritis nos 
N05zN00 osteoarthritis nos, of ankle 
N053.00 localised osteoarthritis, unspecified 
N05zJ00 osteoarthritis nos, of hip 
N03x000 arthritis associated with other disease, shoulder 
N05z300 osteoarthritis nos, of the forearm 
N11..12 osteoarthritis of spine 
N05zK00 osteoarthritis nos, of sacro-iliac joint 
N051z00 localised, primary osteoarthritis nos 
N03x800 arthritis associated with other disease, dip joint of finger 
N06z411 hand arthritis nos 
N051F00 localised, primary osteoarthritis of elbow 
N05z412 thumb osteoarthritis nos 
N05z900 osteoarthritis nos, of shoulder 
N06z712 foot arthritis nos 
N051D00 localised, primary osteoarthritis of the wrist 
N053600 localised osteoarthritis, unspecified, of the lower leg 
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N06z711 ankle arthritis nos 
N06zA00 acute arthritis 
7P20400 delivery of rehabilitation for osteoarthritis 
N052600 localised, secondary osteoarthritis of the lower leg 
N05z511 hip osteoarthritis nos 
N052800 localised, secondary osteoarthritis of other specified site 
N052200 localised, secondary osteoarthritis of the upper arm 
N06zB00 chronic arthritis 
N050200 generalised osteoarthritis of multiple sites 
N051G00 osteoarthritis of spinal facet joint 
N054900 oligoarticular osteoarthritis, unspecified, multiple sites 
N05zM00 osteoarthritis nos, of tibio-fibular joint 
14G2.00 h/o: osteoarthritis 
N05zH00 osteoarthritis nos, of dip joint of finger 
N05z800 osteoarthritis nos, other specified site 
N052300 localised, secondary osteoarthritis of the forearm 
N06z611 knee arthritis nos 
N05z100 osteoarthritis nos, of shoulder region 
N052z00 localised, secondary osteoarthritis nos 
N053200 localised osteoarthritis, unspecified, of the upper arm 
N110.12 osteoarthritis cervical spine 
N054700 oligoarticular osteoarthritis, unspecified, of ankle/foot 
N065A00 generalised arthritis 
N03xD00 arthritis associated with other disease, ankle 
N051500 localised, primary osteoarthritis of the pelvic region/thigh 
N05zL00 osteoarthritis nos, of knee 
N051600 localised, primary osteoarthritis of the lower leg 
N05z500 osteoarthritis nos, pelvic region/thigh 
N05z311 wrist osteoarthritis nos 
N054200 oligoarticular osteoarthritis, unspecified, of upper arm 
N05zD00 osteoarthritis nos, of distal radio-ulnar joint 
N05z712 foot osteoarthritis nos 
14G..11 h/o: arthritis 
27 
 
N06z511 hip arthritis nos 
N052.00 localised, secondary osteoarthritis 
N11..11 arthritis of spine 
N053z00 localised osteoarthritis, unspecified, nos 
N054500 oligoarticular osteoarthritis, unspecified, of pelvis/thigh 
N11D000 osteoarthritis of cervical spine 
N05zE00 osteoarthritis nos, of wrist 
N06z.11 arthritis 
N051400 localised, primary osteoarthritis of the hand 
N03x200 arthritis associated with other disease, acromioclavic joint 
66H..11 arthritis monitoring 
N05z611 knee osteoarthritis nos 
N051100 localised, primary osteoarthritis of the shoulder region 
N03x400 arthritis associated with other disease, dist rad-uln joint 
N05z211 elbow osteoarthritis nos 
N054100 oligoarticular osteoarthritis, unspecified, of shoulder 
N05zG00 osteoarthritis nos, of pip joint of finger 
N03xE00 arthritis associated with other disease, subtalar joint 
N05z600 osteoarthritis nos, of the lower leg 
N03x700 arthritis associated with other disease, pip joint of finger 
N11D100 osteoarthritis of thoracic spine 
N03x100 arthritis associated with other disease, sternoclavic joint 
N05zR00 osteoarthritis nos, of other tarsal joint 
N051700 localised, primary osteoarthritis of the ankle and foot 
N063800 climacteric arthritis of other specified site 
N05z411 finger osteoarthritis nos 
N05z700 osteoarthritis nos, of ankle and foot 
N06z211 elbow arthritis nos 
N11D.00 osteoarthritis of spine 
N03x900 arthritis associated with other disease, hip 
N11D200 osteoarthritis of lumbar spine 
N050z00 generalised osteoarthritis nos 
N050100 generalised osteoarthritis of the hand 
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N05z400 osteoarthritis nos, of the hand 
N053611 patellofemoral osteoarthritis 
N05z200 osteoarthritis nos, of the upper arm 
N05zQ00 osteoarthritis nos, of talonavicular joint 
N06z311 wrist arthritis nos 
N03xH00 arthritis associated with other disease, 1st mtp joint 
N052500 localised, secondary osteoarthritis of pelvic region/thigh 
N05zT00 osteoarthritis nos, of lesser mtp joint 
N05zP00 osteoarthritis nos, of subtalar joint 
N054000 oligoarticular osteoarthritis, unspec, of unspecified sites 
N054.00 oligoarticular osteoarthritis, unspecified 
N051800 localised, primary osteoarthritis of other specified site 
N05zB00 osteoarthritis nos, of acromioclavicular joint 
N05z000 osteoarthritis nos, of unspecified site 
N054z00 osteoarthritis of more than one site, unspecified, nos 
N050.00 generalised osteoarthritis - oa 
N051E00 localised, primary osteoarthritis of toe 
N054800 oligoarticular osteoarthritis, unspecified, other spec sites 
N053300 localised osteoarthritis, unspecified, of the forearm 
N03x500 arthritis associated with other disease, wrist 
N051300 localised, primary osteoarthritis of the forearm 
Nyu1B00 [x]other specified arthritis 
N03xJ00 arthritis associated with other disease, lesser mtp joint 
N05z.00 osteoarthritis nos 
N051200 localised, primary osteoarthritis of the upper arm 
N053800 localised osteoarthritis, unspecified, of other spec site 
N03xG00 arthritis associated with other disease, other tarsal joint 
N054600 oligoarticular osteoarthritis, unspecified, of lower leg 
N05zC00 osteoarthritis nos, of elbow 
N05zU00 osteoarthritis nos, of ip joint of toe 
N050000 generalised osteoarthritis of unspecified site 
N051000 localised, primary osteoarthritis of unspecified site 
ZV13400 [v]personal history of arthritis 
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N054400 oligoarticular osteoarthritis, unspecified, of hand 
N053500 localised osteoarthritis, unspecified, pelvic region/thigh 
N03xB00 arthritis associated with other disease, knee 
N06z111 shoulder arthritis nos 
N05z711 ankle osteoarthritis nos 
N052100 localised, secondary osteoarthritis of the shoulder region 
N053700 localised osteoarthritis, unspecified, of the ankle and foot 
N05..11 osteoarthritis 
N03xA00 arthritis associated with other disease, sacro-iliac joint 
N053100 localised osteoarthritis, unspecified, of shoulder region 
N03xK00 arthritis associated with other disease, ip joint of toe 
N052400 localised, secondary osteoarthritis of the hand 
N052700 localised, secondary osteoarthritis of the ankle and foot 
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S5 The distribution of exposures, outcomes and potential confounders across patients with complete 
and incomplete data 
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Variable 
 
Complete records 
(n=5,075) 
Incomplete records 
(n=1,745) 
Exposure (presence of)   
   Cerebral palsy 1263 (24.9) 442 (25.3) 
Presence of   
    Wrist fracture 71 (1.4) 15 (0.9) 
Sex   
   Males  2533 (49.9)  1095 (62.3) 
Age, yr   
   Median (IQR) 32 (22 to 45) 21 (18 to 31) 
   <30  2242 (44.2) 1266 (72.6) 
   30-39 1132 (22.3)  212 (12.2)  
   40-49 771 (15.2)  121 (6.9)  
   50-59 494 (9.7)  46 (2.6)  
   ≥60 436 (8.6)  100 (5.7)  
Smoking status   
   Current smoker 1416 (27.9)_ 308 (17.7)  
   Ex-smoker 418 (8.2)  71 (4.1)  
   Non-smoker 3241 (63.9)  760 (43.6)  
    Missing 0 (0) 606 (34.7) 
Alcohol consumption   
   Current drinker 3855 (76.0)  11 (0.6)  
   Ex-drinker 55 (1.1)  0 (0)  
   Non-drinker 1165 (23.0)  2 (0.1) 
   Missing 0 (0) 1732 (99.3) 
Practice regiona   
   North England and Scotland 1442 (28.4)  450 (25.8)  
   Midlands and Wales 1705 (33.6)  707 (40.5)  
   South England 1795 (35.4)  553 (31.7)  
   Northern Ireland 133 (2.6)  35 (2.0)  
Outcome (presence of)   
   OA  440 (8.7) 34 (2.0) 
   RA  68 (1.3)  7 (0.4) 
   OP  85 (1.7)  11 (0.6) 
Average yearly GP visits (OA)   
Median (IQR)  4.96 (2.26 to 9.37) 2.44 (0.87 to 6.56) 
Range 0 to 133.63 0 to 154.70 
   0 - 1.9 visits 1128 (22.2)  775 (44.4)  
   2 - 11.9 visits 3088 (60.9)  769 (44.1)  
   ≥ 12 visits 859 (16.9)  201 (11.5)  
Average yearly GP visits (RA)   
Median (IQR) 5.42 (2.63 to 10.03) 2.52 (0.90 to 6.71) 
Range 0 to 133.63 0 to 154.70 
   0 - 1.9 visits 974 (19.2)  763 (43.7) 
   2 - 11.9 visits 3142 (61.9)  776 (44.5) 
   ≥ 12 visits 959 (18.9)  206 (11.8) 
Average yearly GP visits (OP)   
Median (IQR) 5.38 (2.64 to 10.00) 2.52 (0.88 to 6.71) 
32 
 
 
 
S6 The distribution of data relating to BMI, smoking status and alcohol status, before and after 
imputation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Range 0 to 133.63 0 to 154.70 
   0 - 1.9 visits 972 (19.2)  763 (43.7)  
   2 - 11.9 visits 3151 (62.1)  773 (44.3)  
   ≥ 12 visits 952 (18.8)  209 (12.0)  
Variable Before imputation After imputation  
Smoking status, n (%) 
   Current smoker 1,724 (25·3) 1,724 (25·3) 
   Ex-smoker 489 (7·2) - 
   Non-smokera 4,001 (58·7) 5,096 (74·7) 
   Missing 606 (8·9) - 
Alcohol consumption, n (%) 
   Current drinker 3,866 (56·7) 5,598 (82·1) 
   Ex-drinker 55 (0·8) - 
   Non-drinkerb 1,167 (17·1) 1,222 (17·9) 
   Missing 1,732 (25·4) - 
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